



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/963,686	09/27/2001	Andrew Stocker	056291-5057	9682
9629	7590 08/31/2004		EXAMINER	
MORGAN LEWIS & BOCKIUS LLP 1111 PENNSYLVANIA AVENUE NW			RAYMOND, RICHARD L	
	ON, DC 20004		ART UNIT	PAPER NUMBER
			1624	

DATE MAILED: 08/31/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/963,686	STOCKER ET AL.
Office Action Summary	Examiner	Art Unit
	Richard L. Raymond	1624
The MAILING DATE of this communication Period for Reply	appears on the cover sheet wit	h the correspondence address
A SHORTENED STATUTORY PERIOD FOR REITHE MAILING DATE OF THIS COMMUNICATION  - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a lift NO period for reply is specified above, the maximum statutory perion from the period for reply will, by state and the period for reply will be period for reply will, by state and the period for reply will be period	N. 1.136(a). In no event, however, may a re reply within the statutory minimum of thirty iod will apply and will expire SIX (6) MONT	(30) days will be considered timely.  HS from the mailing date of this communication.
Status		
1) Responsive to communication(s) filed on 12		
	his action is non-final.	
3) Since this application is in condition for allow		
closed in accordance with the practice unde	er Ex parte Quayle, 1935 C.D.	11, <b>4</b> 53 O.G. 213.
Disposition of Claims		
4)⊠ Claim(s) <u>1-14</u> is/are pending in the application		
4a) Of the above claim(s) is/are withd	rawn from consideration.	
5) ☐ Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>1-14</u> is/are rejected.		
7) Claim(s) is/are objected to.	Mon alastias sa suite es et	
8) Claim(s) are subject to restriction and	i/or election requirement.	
Application Papers		
9) The specification is objected to by the Exami	ner.	
10)☐ The drawing(s) filed on is/are: a)☐ ad	ccepted or b) abjected to by	the Examiner.
Applicant may not request that any objection to th	ne drawing(s) be held in abeyance	e. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the corre	ection is required if the drawing(s)	) is objected to. See 37 CFR 1.121(d).
11) ☐ The oath or declaration is objected to by the l	Examiner. Note the attached (	Office Action or form PTO-152.
Priority under 35 U.S.C. § 119		
12)☐ Acknowledgment is made of a claim for foreig	gn priority under 35 U.S.C. § 1	19(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority docume		
2. Certified copies of the priority docume	nts have been received in App	olication No
3. Copies of the certified copies of the pri	ority documents have been re	ceived in this National Stage
application from the International Bure  * See the attached detailed Office action for a life		
* See the attached detailed Office action for a lis	or or the certified copies not re	ceived.
Attachment(s)		
1) \( \sum \) Notice of References Cited (PTO-892) \( \sum \) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Sum	nmary (PTO-413) fail Date
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SR/08	3) 5) L Notice of Infor	mal Patent Application (PTO-152)
Paper No(s)/Mail Date	6) 🔲 Other:	

Application/Control Number: 09/963,686

Art Unit: 1624

#### **DETAILED ACTION**

#### Election/Restrictions

1. Pursuant to the requirement for election of species, applicants have elected the compound of Example 9, a compound under the present generic formula where A is a pyridazinyl ring and  $-T^1(R^2)-L^1-T^2(R^3)$ - together form a piperazinyl ring. Claims 1-14 are readable thereon.

# Improper Markush Rejection

2. Claims 1-7 and 10-14 are rejected as being improper Markush claims in the definition of the A variable as heteroaryl containing only nitrogen atoms and other heteroaryl groups and -T<sup>1</sup>(R<sup>2</sup>)-L<sup>1</sup>-T<sup>2</sup>(R<sup>3</sup>)- being piperazine, other heterocyclic groups and nonheterocyclic groups. So substituted, the resulting total compounds lack a common core and are structurally diverse and patentable distinct one from the others. A reference anticipating one under 35 USC 102 would not be a reference against the others under 35 USC 103. Further, an undue search burden in the U.S. classification system (various subclasses in classes 540, 544, 546, 546, 549, 560, 562, 564 and 568, and the corresponding subclasses of use class 514) and the literature (STN/CAS) is involved. Limitation of the claims to compounds where A is N-heteroaryl and -T<sup>1</sup>(R<sup>2</sup>)-L<sup>1</sup>-T<sup>2</sup>(R<sup>3</sup>)- forms a piperazine ring, encompassing the elected species, will overcome this rejection.

Application/Control Number: 09/963,686

Art Unit: 1624

Page 3

3. The claims have been searched and examined to the extent that they read on the above grouped invention.

## Obviousness-type Double Patenting

4. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

5. Claims 1-14 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-12 of parent U.S. Patent No. 6,300,330. Although the conflicting claims are not identical, they are not patentably distinct from each other because the  $T^1(R^2)$ - $L^1$ - $T^2(R^3)$  grouping of the patent claims forms a piperazinyl ring which anticipate the present claims where the  $T^1(R^2)$ - $L^1$ - $T^2(R^3)$  grouping can be a piperazinyl ring, other N rings or non-cyclic groups. Where not anticipating the present claims, the claims of the patent render the present claims structurally obvious.

Art Unit: 1624

6. Claims 1-14 are further provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-13 of copending Reissue Application No. 10/391,025 (a reissue of U.S. Patent No. 6,300,330, above). See the reasons above. This is a <u>provisional</u> obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

## Claim Rejections - 35 USC § 112

7. Claims 1-7 and 10-14 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. (1) The use of the language "for example" and "preferably" in claim 1 renders that claim and claims 2-7 and 10-14 dependent thereon indefinite. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. (2) Claims 5-7 and 10-13 are multiple dependent claims improperly dependent on other multiple dependent claims. (3) The term "pyradazinyl" in claim 8 should apparently read -- pyridazinyl --. (4) Claim 10 is a substantial duplicate of the claims on which it depends since no patentable significance is given to statements of intended use in compound claims. (5) Claim 12 provides for the use of compounds, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite

Art Unit: 1624

where it merely recites a use without any active, positive steps delimiting how this use is actually practiced. Correction and/or clarification of the above criticisms is requested.

#### Information Disclosure Statement

8. It is requested that a Form PTO-1449 citing the prior art of record in the parent application be supplied to complete the record.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Richard L. Raymond whose telephone number is (571) 272-0673. The examiner can normally be reached on maxi-flex.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on (571) 272-0674. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Primary Examiner

Art Unit 1624

rr

August 25, 2004